Substance / Medication

Belumosudil

Overview

Active Ingredient

belumosudil

RxNorm CUI

2564025

Indications

REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

Labeler: Kadmon Pharmaceuticals, LLCUpdated: 2026-02-03T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Graft versus host disease

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

NCT06616415Phase 4Active Not Recruiting6 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.

Gadelmawla Ahmed Farid, Alsaied Mohamed A, Alkuwaiti Mohanad A et al. · Clin Transplant · 2026

PMID: 41556727Meta-Analysis

Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation-a systematic review.

Barbalho Sandra Maria, de Alvares Goulart Ricardo, Minniti Giulia et al. · Naunyn Schmiedebergs Arch Pharmacol · 2024

PMID: 37966572Meta-Analysis

Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study.

Chung Lorinda, Silver Richard M, Steen Virginia et al. · Rheumatology (Oxford) · 2025

PMID: 40088930RCTFull text (PMC)

Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.

Hall Kevin, Lazaryan Aleksandr, van der Laan Mark et al. · Blood Adv · 2026

PMID: 40875591Observational

Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.

Rodriguez-Rodriguez Sergio, Desai Nihar, Lemieux Christopher et al. · Ann Hematol · 2025

PMID: 41136748ObservationalFull text (PMC)

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.

Heidenreich Silke, Egger-Heidrich Katharina, Halter Jörg P et al. · Bone Marrow Transplant · 2025

PMID: 39809902ObservationalFull text (PMC)

Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy.

Michonneau David, Malard Florent, Le Grand Sophie et al. · Bone Marrow Transplant · 2025

PMID: 40169928ObservationalFull text (PMC)

An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.

Inamoto Yoshihiro, Kato Koji, Kawakita Toshiro et al. · Am J Hematol · 2024

PMID: 38934629Observational

A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.

Wang Ying, Wu Depei, Zhang Xiang et al. · BMC Med · 2024

PMID: 38532458ObservationalFull text (PMC)

Comparative transcriptome profile of mouse macrophages treated with the RhoA/Rock pathway inhibitors Y27632, Fingolimod (Gilenya), and Rezurock (Belumosudil, SLx-2119).

Subuddhi Arijita, Uosef Ahmed, Zou Dawei et al. · Int Immunopharmacol · 2023

PMID: 36931169Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Belumosudil (substance)
SNOMED CT: 1163566003
UMLS CUI: C5418179
RxNorm CUI: 2564025
Labeler: Kadmon Pharmaceuticals, LLC

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.